Vera Therapeutics (VERA) News Today

Cantor Fitzgerald restated an "overweight" rating and issued a $107.00 price target on shares of Vera Therapeutics in a report on Friday.

Vera Therapeutics (NASDAQ:VERA) Stock Price Up 5.5% After Analyst Upgrade

JPMorgan Chase & Co. lifted their price target on Vera Therapeutics from $62.00 to $72.00 and gave the stock an "overweight" rating in a report on Tuesday.

Legato Capital Management LLC purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,551 shares of the company's stock, va

EFG Asset Management North America Corp. grew its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 204.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,444 shares o

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 14,471 shares of the company's stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total value of $575,366.96. Following the sale, the chief executive officer now owns 322,667 shares of the company's stock, valued at approximately $12,829,239.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vera Therapeutics (NASDAQ:VERA) Trading 3.5% Higher

William Marsh Rice University purchased a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 16,397 shares of the company's stock, val

JPMorgan Chase & Co. cut their target price on shares of Vera Therapeutics from $65.00 to $62.00 and set an "overweight" rating on the stock in a research note on Tuesday.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) issued its earnings results on Thursday. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06).

Vanguard Group Inc. grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 31.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,148,714 shares of the company's stock after buying an additional 515,106 sh

Cambridge Trust Co. increased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 386.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,107 shares of the company's st

Russell Investments Group Ltd. raised its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3,526.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,209 shares of the comp

Price T Rowe Associates Inc. MD bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,393,029 shares of the

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been given an average recommendation of "Buy" by the eight research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rat

Lord Abbett & CO. LLC acquired a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 225,581 shares of the company's stock, valued at approximatel

Jennison Associates LLC bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund bought 74,939 shares of the company's stock, valued at approximately $3,231,000. Jennison Associa

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have received a consensus rating of "Buy" from the eight analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommen

Vera Therapeutics (NASDAQ:VERA) Trading Down 4.5%

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down to $38.00

Schroder Investment Management Group purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,110,960 shares of th

Kynam Capital Management LP lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 23.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,650,339 shares of the company's stock after buying an addi

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has received an average rating of "Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and

Rafferty Asset Management LLC boosted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 25.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,758 shares of the company's stock

Sectoral Asset Management Inc. trimmed its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 65.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,151 shares o

JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $60.00 to $65.00 and gave the stock an "overweight" rating in a research note on Friday.

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up to $37.11